Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs » Research

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

A Once-A-Year Continuous Exenatide Therapy Shows 100% Compliance Posted: Sunday, October 10, 2010

Implantable device promises diabetes patients continuous exenatide therapy with 100% compliance. Tolerability and weight loss was better with ITCA 650 20 μg/day than with exenatide injections.

Kidney Function in Patients with Diabetic Nephropathy Linked to Seasonal BP Posted: Sunday, October 10, 2010

Researchers say clinicians should consider seasonal variations in systolic blood pressure when treating patients with diabetic nephropathy, after finding seasonal variations in urinary albumin-to-creatinine ratio (UACR), likely linked to blood-pressure changes.

Diabetes Risk Falls as Magnesium Intake Increases Posted: Sunday, October 10, 2010

Getting enough magnesium in your diet could help prevent diabetes, a new study suggests. Consuming 200 milligrams of magnesium for every 1,000 calories reduces risk of diabetes by 47%.

EASD: Pioglitazone-Sitagliptin Combination Achieves Durable Glycemic Control Posted: Sunday, October 03, 2010

Adding 50 mg of sitagliptin (Januvia) to pioglitazone (Actos) allowed patients with Type 2 diabetes to achieve sustained glycemic control, a yearlong trial showed.

EASD: New Drug Classes Entering Type 2 Pipeline Posted: Sunday, October 03, 2010

Farnesoid X receptor agonists, 11-â-HSD1 inhibitors, and glucokinase activators are some of the new approaches to treating Type 2 diabetes described in research presented, but some senior researchers expressed doubts about the clinical need for them.

EASD: Once-Weekly Exenatide Benefit Sustained over 52 Weeks Posted: Sunday, October 03, 2010

Once-Weekly Exenatide maintains a drop in A1c of 2 points for more than 52 weeks.

EASD: Moderate Wine Drinking Lowers Fasting Glucose in Type 2 Diabetes Posted: Sunday, October 03, 2010

A glass of merlot or perhaps sauvignon blanc with dinner may offer modest benefits for patients with Type 2 diabetes, said researchers.

EASD: Fracture Risk Demands Attention in Diabetes Patients Posted: Sunday, October 03, 2010

Because Type 2 diabetes weakens the bone in often undetectable ways, both directly and indirectly via treatment side effects, experts urged increased awareness.

EASD: Frequent Hypoglycemia Key in Cardiac Risk Posted: Sunday, October 03, 2010

Patients with Type 1 diabetes who have repeated episodes of hypoglycemia appear to be at risk for early signs of atherosclerosis, researchers said.

EASD: Weight Loss with SGLT2 Inhibitors but More Infections Posted: Sunday, October 03, 2010

Three possible first in class drugs in the sodium glucose co-transporter (SGLT2 inhibitor) class showed improvements in glycemic control and weight loss, but infections proved troublesome, researchers reported.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.